{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T22:52:29Z","timestamp":1785883949679,"version":"3.56.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","award":["U01FD007934"],"award-info":[{"award-number":["U01FD007934"]}],"id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AG06688"],"award-info":[{"award-number":["R01AG06688"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011542","name":"Mayo Clinic Center for Clinical and Translational Science","doi-asserted-by":"publisher","award":["UL1TR002377"],"award-info":[{"award-number":["UL1TR002377"]}],"id":[{"id":"10.13039\/100011542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials Communications"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.conctc.2026.101653","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T06:20:24Z","timestamp":1780986024000},"page":"101653","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The design of a small Bayesian hybrid-controlled trial utilizing time-to-event data from six published sources that used best alternative care to treat liver-predominant metastasis from primary ocular melanoma"],"prefix":"10.1016","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0529-5146","authenticated-orcid":false,"given":"David","family":"Zahrieh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetomir N.","family":"Markovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera J.","family":"Suman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.conctc.2026.101653_bib1","article-title":"Comparative study of bayesian information borrowing methods in oncology clinical trials","volume":"6","author":"Su","year":"2022","journal-title":"JCO Precis. Oncol."},{"issue":"1","key":"10.1016\/j.conctc.2026.101653_bib2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/pst.1589","article-title":"Use of historical control data for assessing treatment effects in clinical trials","volume":"13","author":"Viele","year":"2014","journal-title":"Pharm. Stat."},{"issue":"1","key":"10.1016\/j.conctc.2026.101653_bib3","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s13023-022-02342-5","article-title":"Application of bayesian methods to accelerate rare disease drug development: scopes and hurdles","volume":"17","author":"Kidwell","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.conctc.2026.101653_bib4","article-title":"A note on the amount of information borrowed from external data in hybrid controlled trials with time-to-event outcomes","author":"Segal","year":"2020","journal-title":"arXiv preprint"},{"issue":"1","key":"10.1016\/j.conctc.2026.101653_bib5","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41572-020-0158-0","article-title":"Uveal melanoma","volume":"6","author":"Jager","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"1","key":"10.1016\/j.conctc.2026.101653_bib6","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1136\/bjophthalmol-2016-309034","article-title":"Metastatic disease from uveal melanoma: treatment options and future prospects","volume":"101","author":"Carvajal","year":"2017","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.conctc.2026.101653_bib7","article-title":"Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases, first results from a phase III randomized controlled multicenter trial (the SCANDIUM trial)","volume":"40","author":"Bagge","year":"2022","journal-title":"J. Clin. Orthod."},{"issue":"4","key":"10.1016\/j.conctc.2026.101653_bib8","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1245\/s10434-015-4968-3","article-title":"Results of a randomized controlled multicenter phase III trial of percutaneous hepatic perfusion compared with best available care for patients with Melanoma liver metastases","volume":"23","author":"Hughes","year":"2016","journal-title":"Ann. Surg Oncol."},{"issue":"3","key":"10.1016\/j.conctc.2026.101653_bib9","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/annonc\/mdt585","article-title":"Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial","volume":"25","author":"Leyvraz","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.conctc.2026.101653_bib10","article-title":"First interim analysis of the SirTac trial: a randomized phase II study of SIRT and DSM-TACE in patients with liver metastases from uveal melanoma","volume":"40","author":"Peuker","year":"2022","journal-title":"J. Clin. Orthod."},{"issue":"4","key":"10.1016\/j.conctc.2026.101653_bib11","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jvir.2014.11.037","article-title":"Double-blinded, randomized phase II study using embolization with or without granulocyte-macrophage colony-stimulating factor in uveal melanoma with hepatic metastases","volume":"26","author":"Valsecchi","year":"2015","journal-title":"J. Vasc. Intervent. Radiol."},{"key":"10.1016\/j.conctc.2026.101653_bib12","article-title":"FOCUS phase 3 trial results: percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases (PHP-OCM-301\/301A)","volume":"40","author":"Zager","year":"2022","journal-title":"J. Clin. Orthod."},{"issue":"13","key":"10.1016\/j.conctc.2026.101653_bib13","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall survival benefit with tebentafusp in metastatic uveal melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.conctc.2026.101653_bib14","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0021-9681(76)90044-8","article-title":"The combination of randomized and historical controls in clinical trials","volume":"29","author":"Pocock","year":"1976","journal-title":"J. Chron. Dis."},{"issue":"1","key":"10.1016\/j.conctc.2026.101653_bib15","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13023-020-1332-x","article-title":"A roadmap to using historical controls in clinical trials - by drug information association adaptive design scientific working group (DIA-ADSWG)","volume":"15","author":"Ghadessi","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"issue":"6","key":"10.1016\/j.conctc.2026.101653_bib16","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/1740774520944855","article-title":"Summarising salient information on historical controls: a structured assessment of validity and comparability across studies","volume":"17","author":"Hatswell","year":"2020","journal-title":"Clin. Trials"},{"issue":"10","key":"10.1016\/j.conctc.2026.101653_bib17","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1177\/0962280217694506","article-title":"Including historical data in the analysis of clinical trials: is it worth the effort?","volume":"27","author":"van Rosmalen","year":"2018","journal-title":"Stat. Methods Med. Res."},{"issue":"1","key":"10.1016\/j.conctc.2026.101653_bib18","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","article-title":"IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Med. Res. Methodol."},{"issue":"4","key":"10.1016\/j.conctc.2026.101653_bib19","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/bimj.201500236","article-title":"Meta-analysis of two studies in the presence of heterogeneity with applications in rare diseases","volume":"59","author":"Friede","year":"2017","journal-title":"Biom. J."},{"issue":"4","key":"10.1016\/j.conctc.2026.101653_bib20","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/jrsm.1475","article-title":"On weakly informative prior distributions for the heterogeneity parameter in Bayesian random-effects meta-analysis","volume":"12","author":"Rover","year":"2021","journal-title":"Res. Synth. Methods"},{"key":"10.1016\/j.conctc.2026.101653_bib21","series-title":"Rstan: the R Interface to Stan","author":"Team","year":"2020"},{"key":"10.1016\/j.conctc.2026.101653_bib22","series-title":"Mixr: Finite Mixture Modeling for Raw and Binned Data","author":"Yu","year":"2024"},{"issue":"1","key":"10.1016\/j.conctc.2026.101653_bib23","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12874-024-02235-0","article-title":"Using Bayesian statistics in confirmatory clinical trials in the regulatory setting: a tutorial review","volume":"24","author":"Lee","year":"2024","journal-title":"BMC Med. Res. Methodol."},{"issue":"17","key":"10.1016\/j.conctc.2026.101653_bib24","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1200\/JCO.2008.20.4107","article-title":"Issues in using progression-free survival when evaluating oncology products","volume":"27","author":"Fleming","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.conctc.2026.101653_bib25","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/biom.12242","article-title":"Robust meta-analytic-predictive priors in clinical trials with historical control information","volume":"70","author":"Schmidli","year":"2014","journal-title":"Biometrics"},{"issue":"28","key":"10.1016\/j.conctc.2026.101653_bib26","doi-asserted-by":"crossref","first-page":"7199","DOI":"10.1200\/JCO.2005.01.149","article-title":"Design issues of randomized phase II trials and a proposal for phase II screening trials","volume":"23","author":"Rubinstein","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.conctc.2026.101653_bib27","first-page":"163","article-title":"Evaluation of survival data and two new rank order statistics arising in its consideration","volume":"50","author":"Mantel","year":"1966","journal-title":"Cancer Chemother. Rep."},{"issue":"2","key":"10.1016\/j.conctc.2026.101653_bib28","first-page":"99","article-title":"Type I error inflation of log-rank test with small sample size: a permutation approach and simulation studies","volume":"53","author":"Wang","year":"2019","journal-title":"J. Statistical Res."},{"issue":"1","key":"10.1016\/j.conctc.2026.101653_bib29","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/1740774509356002","article-title":"Summarizing historical information on controls in clinical trials","volume":"7","author":"Neuenschwander","year":"2010","journal-title":"Clin. Trials"},{"issue":"4","key":"10.1016\/j.conctc.2026.101653_bib30","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/ajmg.c.31533","article-title":"Alternative designs for clinical trials in rare diseases","volume":"172","author":"Abrahamyan","year":"2016","journal-title":"Am. J. Med. Genet. Part C-Seminars in Medical Genetics"},{"issue":"1","key":"10.1016\/j.conctc.2026.101653_bib31","doi-asserted-by":"crossref","DOI":"10.1038\/s43586-022-00100-2","article-title":"Designing clinical trials for rare diseases: unique challenges and opportunities","volume":"2","author":"Pizzamiglio","year":"2022","journal-title":"Nat. Rev. Methods Primers"},{"issue":"15","key":"10.1016\/j.conctc.2026.101653_bib32","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1016\/j.ejca.2012.06.013","article-title":"Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline--Update 2012","volume":"48","author":"Garbe","year":"2012","journal-title":"Eur. J. Cancer"},{"issue":"13\u201314","key":"10.1016\/j.conctc.2026.101653_bib33","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1002\/sim.4780131321","article-title":"Stopping when the experimental regimen does not appear to help","volume":"13","author":"Wieand","year":"1994","journal-title":"Stat. Med."},{"issue":"3","key":"10.1016\/j.conctc.2026.101653_bib34","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1214\/12-BA722","article-title":"Commensurate priors for incorporating historical information in clinical trials using general and generalized linear models","volume":"7","author":"Hobbs","year":"2012","journal-title":"Bayesian Analysis"},{"issue":"1","key":"10.1016\/j.conctc.2026.101653_bib35","first-page":"46","article-title":"Power prior distributions for regression models","volume":"15","author":"Ibrahim","year":"2000","journal-title":"Stat. Sci."},{"issue":"1","key":"10.1016\/j.conctc.2026.101653_bib36","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/biom.13551","article-title":"Elastic priors to dynamically borrow information from historical data in clinical trials","volume":"79","author":"Jiang","year":"2023","journal-title":"Biometrics"},{"key":"10.1016\/j.conctc.2026.101653_bib37","series-title":"Bayesian Methods in Pharmaceutical Research","article-title":"Bayesian frameworks for rare disease clinical development programs","author":"Cooner","year":"2020"},{"key":"10.1016\/j.conctc.2026.101653_bib38","series-title":"Bayesian Methods in Pharmaceutical Research","first-page":"111","article-title":"Use of historical data","author":"Neuenschwander","year":"2020"},{"issue":"6","key":"10.1016\/j.conctc.2026.101653_bib39","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1177\/17407745211050580","article-title":"The U.S. food and drug administration's complex innovative trial design pilot meeting program: progress to date","volume":"18","author":"Price","year":"2021","journal-title":"Clin. Trials"},{"issue":"4","key":"10.1016\/j.conctc.2026.101653_bib40","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/cpt.1723","article-title":"Beyond randomized clinical trials: use of external controls","volume":"107","author":"Schmidli","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.conctc.2026.101653_bib42","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/pst.1736","article-title":"Idle thoughts of a 'well-calibrated' Bayesian in clinical drug development","volume":"15","author":"Grieve","year":"2016","journal-title":"Pharm. Stat."},{"key":"10.1016\/j.conctc.2026.101653_bib43","series-title":"International Conference on Machine Learning","article-title":"Robust estimation and inference in hybrid controlled trials for binary outcomes: a case study on non-small cell lung cancer","author":"Liu","year":"2025"},{"key":"10.1016\/j.conctc.2026.101653_bib44","series-title":"International Conference on Machine Learning","article-title":"Enhancing statistical validity and power in hybrid controlled trials: a randomization inference approach with conformal selective borrowing","author":"Zhu","year":"2025"},{"issue":"8","key":"10.1016\/j.conctc.2026.101653_bib45","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDe2300142","article-title":"Breaking free from the hazard ratio: embracing the restricted mean survival time in clinical trials","volume":"2","author":"Han","year":"2023","journal-title":"NEJM Evid."}],"container-title":["Contemporary Clinical Trials Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451865426000608?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451865426000608?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T22:26:11Z","timestamp":1785882371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451865426000608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":44,"alternative-id":["S2451865426000608"],"URL":"https:\/\/doi.org\/10.1016\/j.conctc.2026.101653","relation":{},"ISSN":["2451-8654"],"issn-type":[{"value":"2451-8654","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The design of a small Bayesian hybrid-controlled trial utilizing time-to-event data from six published sources that used best alternative care to treat liver-predominant metastasis from primary ocular melanoma","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.conctc.2026.101653","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101653"}}